Business Context and Reporting Period
This Form 8-K is a current report filed by Entero Therapeutics, Inc. (not Gridai Technologies Corp.) on September 9, 2025. The filing reports significant corporate governance changes, specifically the termination of the Interim Chief Executive Officer and Chairman of the Board and the appointment of a successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
- Termination of Leadership: On September 3, 2025, the Board terminated Richard Joel Paolone as Interim CEO and Chairman of the Board without cause, effective immediately. Mr. Paolone remains a director.
- Contract Termination: The consulting agreement between the Company and Mr. Paolone, dated February 12, 2025, was terminated without cause. The Company made a payment in lieu of the contractual notice period.
- Appointment of New Interim CEO: On September 4, 2025, Jason D. Sawyer was appointed as Interim CEO, effective immediately. Mr. Sawyer continues to serve as a director.
Guidance, Outlook, and Management Commentary
Management Commentary: The Board explicitly stated that Mr. Paolone's termination was not due to any disagreement regarding financial reporting, policies, or practices. Mr. Sawyer's compensation as Interim CEO will be determined at a later time.
Outlook and Risks: The filing does not provide specific business guidance, risk factors, or contingencies beyond the immediate leadership transition. Mr. Sawyer brings over 32 years of experience in the alternative investment industry, having raised over $5 billion in assets and deployed over $300 million in early-stage investments across various sectors including biotech and fintech.
Investor Verification Checklist
- Verify the exact terms of the "payment in lieu of notice" made to Richard Joel Paolone in subsequent filings or proxy statements.
- Monitor future announcements regarding the compensation package for Jason D. Sawyer as Interim CEO.
- Confirm whether the leadership change impacts the Company's strategic direction or ongoing clinical/operational programs.
- Review the Company's most recent 10-K or 10-Q for actual financial health metrics, as this 8-K contains none.